Artículos del autor

solaci

DAY 2

CENTERA: Results of the New Self-Expandable Valve

This new device offers the advantage of a lower frame height, which reduces the chance of coronary...
solaci -
Antiplatelet

ARTE: Aspirin or Aspirin and Clopidogrel after TAVR?

Courtesy of SBHCI. This study presented at Euro PCR and simultaneously published by JACC Cardiovascular Interventions poses a...
solaci -
Peripheral vascular disease

Second-Generation DES Present Lower Mortality Rates for Vein Grafts

Courtesy of Dr. Carlos Fava. The treatment of vein graft lesions has always been difficult in relation to angioplasty,...
solaci -
Mitral valve

Bad prognosis for post-MitraClip mitral valve stenosis: how do we proceed?

Courtesy of Dr. Carlos Fava The EVEREST II trial showed the MitraClip had similar mortality rate to that...
solaci -
Acute coronary syndromes

DEFINE FLAIR and IFR SWEDEHEART: Safety in Revascularization Based on FFR and iFR in Both Stable and ACS Patients

The safety of physiology-based coronary revascularisation has been supported by evidence for years now. DEFER (1998-2001) was...
solaci -
Coronary disease

DESSOLVE III: Xience vs. MiStent

The MiStent device is made of cobalt-chromium, with struts of up to 64 µm thick. It is coated...
solaci -
DAY 1

REPRISE III: Lotus and CoreValve Compared in High-Risk or Inoperable Patients

The efficacy of transcatheter aortic valve replacement (TAVR) has been well-established. However, its limitations include suboptimal deployment...
solaci -
Antiplatelet

TOPIC: Benefits of Switching Dual Antiplatelet Therapy in Patients with ACS

Newer P2Y12 blockers are the front-line treatment and dual antiplatelet therapy is indicated for 1 year after acute...
solaci -